Lactocore Group leverages milk peptides to combat inflammaging

CC-98633 by Bristol-Myers Squibb for Relapsed Multiple Myeloma: Likelihood of Approval

CC-98633 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Relapsed Multiple Myeloma.

February 21, 2024

How Numinus Wellness Is Reacting To Lykos’ Rebrand

Join Shadd Dales, host, and founder of The Dales Report Trade To Black podcast as he interviews Payton Nyquvest, Co-founder, Chair, and CEO of Numinus

January 8, 2024

New study classifies CSU skin eruptions into five categories using mathematical modeling

Chronic spontaneous urticaria (CSU), a skin condition marked by sudden eruptions.

December 6, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.